Last reviewed · How we verify
Tamiflu (verum)
Tamiflu inhibits neuraminidase, an enzyme on the surface of influenza viruses, preventing viral release from infected cells and reducing viral spread.
Tamiflu inhibits neuraminidase, an enzyme on the surface of influenza viruses, preventing viral release from infected cells and reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.
At a glance
| Generic name | Tamiflu (verum) |
|---|---|
| Sponsor | National Institute for Public Health and the Environment (RIVM) |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Oseltamivir (Tamiflu) is a prodrug that is converted in the body to its active form, which binds to and inhibits influenza neuraminidase. This enzyme normally cleaves sialic acid receptors on host cells, allowing newly formed virus particles to escape. By blocking this step, the drug traps viral particles on the cell surface and reduces transmission to neighboring cells, thereby shortening infection duration and reducing symptom severity.
Approved indications
- Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age
- Prophylaxis of influenza A and B in patients ≥1 year of age
Common side effects
- Nausea
- Vomiting
- Headache
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamiflu (verum) CI brief — competitive landscape report
- Tamiflu (verum) updates RSS · CI watch RSS
- National Institute for Public Health and the Environment (RIVM) portfolio CI